Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
2022 · Leukemia · 71 citations
https://doi.org/10.1038/s41375-022-01576-3
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
126
Citations
5
h-index
3
i10-index
Edoardo Pennesi is an academic researcher from Princess Máxima Center. The author has contributed to research in topics: Acute Lymphoblastic Leukemia research & Chronic Lymphocytic Leukemia Research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 5, co-authored 9 publications.
ORCID: 0000-0002-0920-8372https://doi.org/10.1038/s41375-022-01576-3
https://doi.org/10.1007/s40262-024-01386-z
Click to start Chat